The socioeconomic sectors increasingly rely on prompt and affordable tools to predict climatic conditions. This study uses a decision tree classifier model to identify similar monthly ENSO 3.4 indices from March 2001 to February 2011 through monthly historical ENSO3.4 indices (December 1950 – February 2001). Historical monthly ENSO3.4 indices were used to extract available high-resolution monthly historical precipitation grids (1950-2001) for Mexico and constructed monthly ensembles (March 2001 – February 2011 hindcasts). Formerly, a precipitation categorization of monthly observed and simulated precipitation (2001-2011 hindcasts) was employed. Thereafter, global vector data and spatial map assessments were performed seasonally (winter, spring, summer, and fall). Global KSS and HSS metrics indicated the model approach has skill, especially in the spring and fall. Spatial metrics exposed large areas with hit rates > 0.60 in winter and spring, though in winter and spring (dry seasons), it was due to the precipitation categorization hindcast and observed were within the first classification. Lower hit rates, but still acceptable (> 0.40), were detected in summer and fall (during the rainy season and at the end, respectively) because more precipitation classifications were tested and prone to miss. Spatial Spearman correlations provided specific areas of significant model performances and found that high hit rates during the winter and spring are spurious. Meanwhile, it was also found that during the fall the model approach is reliable in most of Mexico, followed by the spring, and in constraint areas in summer and winter across the country. It also appears that dominant ENSO neutral events followed by balanced ENSO cooling and warming events do not prefer the model skill. Overall, the empirical method shows promise (low-cost human and computational resources if ENSO indices expose certainty in its Lead months to forecast) and has the potential to be used in other developing countries influenced by El Niño phenomena.

In recent years, numerous approaches have been developed to comprehend the molecular altera-tions underlying thyroid cancer (TC) oncogenesis and explore novel therapeutic strategies for TC. It is now well established that the neurokinin-1 receptor (NK-1R) is overexpressed in cancer cells and that NK-1R is essential for viability of cancer cells. The binding of substance P (SP) to NK-1R in neoplastic cells plays a pivotal role in cancer progression by promoting neoplastic cell growth, protecting tumour cells from apoptosis, triggering invasion and metastasis through enhanced migration of cancer cells, and stimulating endothelial cell proliferation for tumour angiogenesis. Remarkably, all types of human TC (papillary, follicular, medullary, anaplastic), as well as met-astatic lesions, exhibit overexpression of SP and NK-1R compared to the normal thyroid gland. TC cells synthesize and release SP, which exerts its multiple functions through autocrine, para-crine, intracrine, and neuroendocrine processes, including the regulation of tumour burden. Con-sequently, the secretion of SP from TC results in increased SP levels in plasma, which are signifi-cantly higher in TC patients compared to controls. Additionally, NK-1R antagonists have demonstrated a dose-dependent antitumour action. They impair cancer cell proliferation on one side and induce apoptosis of tumour cells on the other side. Furthermore, it has been demonstrat-ed that NK-1R antagonists inhibit neoplastic cell migration, thereby impairing both invasiveness and metastatic abilities, as well as angiogenesis. Given the consistent overexpression of NK-1R in all types of TC, targeting this receptor represents a promising therapeutic approach for TC. Therefore, NK-1R antagonists, such as the drug aprepitant, may represent novel drugs for TC treatment.

The use of machine learning (ML) approaches to target clinical problems is called to revolutionize clinical decision-making. The success of these tools is subjected to the understanding of the intrinsic processes being used during the classical pathway by which clinicians make decisions. In a parallelism with this pathway, ML can have an impact at four levels: for data acquisition, predominantly by extracting standardized, high-quality information with the smallest possible learning curve; for feature extraction, by discharging healthcare practitioners from performing tedious measurements on raw data; for interpretation, by digesting complex, heterogeneous data in order to augment the understanding of the patient status; and for decision support, by leveraging the previous step to predict clinical outcomes, response to treatment or to recommend a specific intervention. This paper discusses the state-of-the-art, as well as the current clinical status and challenges associated with each of these tasks, together with the challenges related to the learning process, the auditability/traceability, the system infrastructure and the integration within clinical processes.